Learn about the rationale for using PARP inhibitors in the neoadjuvant treatment of various cancers with homologous recombination repair deficiency, the ongoing clinical trials, and future directions.
Although gastrointestinal adverse events were not uncommon in the trials of the novel agent zolbetuximab, they tended to be transient. This is the first report of delayed-onset and persistent gastritis linked to its use.
Appendiceal tumors occur at a rate of 14.3% in patients with acute appendicitis and periappendicular abscess, supporting the argument for interval appendectomy after conservative management.
Liver metastasis as the first clinical sign of parotid gland adenoid cystic carcinoma is very rare, but shows that salivary gland tumors should be considered in the differential diagnosis of unexplained hepatic lesions.
The incidence of secondary neoplasia in patients with acromegaly has increased in recent years. What are the risk factors for cancer in these patients, which cancers are most common, and how should screening be approached?
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.
Please note, this webinar is not intended for healthcare professionals based in the US and UK.
Although gastrointestinal adverse events were not uncommon in the trials of the novel agent zolbetuximab, they tended to be transient. This is the first report of delayed-onset and persistent gastritis linked to its use.
Liver metastasis as the first clinical sign of parotid gland adenoid cystic carcinoma is very rare, but shows that salivary gland tumors should be considered in the differential diagnosis of unexplained hepatic lesions.
A patient who tested negative for H. pylori and who had been taking a proton pump inhibitor for 3 years developed multiple metachronous foveolar-type gastric adenomas. Could the PPI be responsible?
Colorectal cancer (CRC) results from the accumulation of genetic and epigenetic mutations in large intestinal epithelial cells that oncogenically transform them into adenocarcinomas [ 1 , 2 ]. This form of cancer is the third most common cancer …
As a global health concern, gastric cancer management has been systematized by individual countries and regions into regimented guidelines. To explore international differences, we examined the guidelines of Korea, Japan, Europe, and the United …
Hepatocellular carcinoma (HCC) represents the most prevalent form of primary liver cancer and is the third leading cause of cancer-related mortality on a global scale [ 1 ]. HCC is associated with a poor prognosis, with a 5-year survival rate of …
Cholangiocarcinoma (CCA), arising from the epithelial cells of the intrahepatic and extrahepatic bile ducts, accounts for approximately 3% of all gastrointestinal malignancies and 10–15% of primary liver cancers, albeit with significant variation …
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.
Colorectal cancer (CRC) is the third most frequent cancer and second cause of cancer-related death worldwide. Rectal cancer (RC) accounts for approximately one-third of all CRC cases [ 1 ] and is mainly treated by surgical resection, with or …
Regular exercise reduces the incidence and improves the prognosis of many cancer types, but the underlying mechanisms remain elusive. Evidence suggests that exercise exerts its therapeutic effects through extracellular vesicles (EVs), which are …
Colorectal cancer (CRC) is currently the first and second cause of cancer-specific mortality in men and women under age 50, respectively [ 1 ]. Cancer-specific mortality is largely driven by metastatic spread [ 2 ]. About 15–25% of patients with …
An evaluation of sarcopenia in patients with esophageal cancer, including its incidence, prognostic impact, underlying mechanisms, and therapeutic approaches, as well as practical recommendations to aid multidisciplinary management.
